·The Hindu

Ministry seeks tighter norms for antimicrobials, bulk trade

FlashcardsQuick reviseKey facts. One by one.Start →
In this note
  1. At a Glance
  2. Why in the News
  3. Background & Evolution
  4. Core Static Facts
  5. Multi-Dimensional Analysis
  6. Recent Developments (last 12–18 months)
  7. Prelims Hooks
  8. How States Could License Antibiotics the Centre Never Approved
  9. Why Earlier Bans Did Not Clear the Shelves
  10. The Case Against Centralising, and What It Gets Right
  11. What the Bulk-Drug Licence Leaves Out: Factory Waste
  12. Anchors for Answers
  13. Mains Relevance
  14. Related Topics to Study Next
  15. NCERT Concepts to Revise
  16. Common Errors / Trap Areas
Practice
2 questions on this article
Check the answer for each question, or reveal all at once.
Practice MCQs →

1. At a Glance

  • The Union Health Ministry has proposed amending the New Drugs and Clinical Trials (NDCT) Rules, 2019 so that 'antimicrobials' fall within the definition of 'New Drug' [1].
  • The aim is to stop manufacturing licences for antimicrobial products being granted without adequate regulatory scrutiny, given that antimicrobial resistance (AMR) is a major global public-health concern [1].
  • A second proposal amends the Drugs Rules, 1945 to create a separate application form and licence form for the sale of bulk drugs, distinct from the licensing provisions for formulations [1].
  • Why it matters for UPSC: it links GS-II (health governance, regulation), GS-III (pharma sector, biotechnology) and the One Health approach behind India's NAP-AMR 2.0 [1][2].

2. Why in the News

  • 20 November 2026: The Hindu (Page 6, International edition) reported the Ministry's draft amendments to the NDCT Rules, 2019 and the Drugs Rules, 1945 [1].
  • Context: India released the second version of its National Action Plan on AMR (NAP-AMR 2.0) during World AMR Awareness Week (WAAW) 2025 [2].

3. Background & Evolution

  • Rationale: AMR is a recognised global public-health threat. The worry is that antimicrobial products are being licensed without enough regulatory scrutiny [1].
  • Milestones:
  • 1940: Drugs and Cosmetics Act enacted. It is the parent statute for drug rules [verify].
  • 1945: Drugs Rules framed. The current proposal amends them for bulk-drug sale licensing [1].
  • 2017–2021: India's first NAP-AMR. WHO India describes it as a technical document that summarises the status of AMR containment in India, together with the action plan [3].
  • 2019: NDCT Rules, 2019 notified. They are the rules now proposed for amendment [1].
  • 2025 (WAAW): NAP-AMR 2.0 released [2].
  • Nov 2026: Draft amendments add antimicrobials to the 'New Drug' definition and create a separate bulk-drug sale licence [1].

  • Related earlier steps: Schedule H1 (2013) restricts over-the-counter sale of certain antibiotics; the Chennai Declaration (2012); the "Red Line" campaign on antibiotic packs (2016) [verify].

4. Core Static Facts

Item Fact
Proposing body Union Ministry of Health & Family Welfare [1]
Rules amended (1) New Drugs and Clinical Trials Rules, 2019: 'antimicrobials' added to the 'New Drug' definition [1]
Rules amended (2) Drugs Rules, 1945: separate application form + licence form for sale of bulk drugs [1]
Bulk drug vs formulation The new bulk-drug licence will be distinct from the existing licensing for formulations [1]
Parent Act Drugs and Cosmetics Act, 1940 [verify]
National regulator CDSCO, headed by the Drugs Controller General of India (DCGI), under MoHFW [verify]
Statutory advisory bodies DTAB (technical) and DCC (State–Centre consultative) under the D&C Act [verify]
Policy framework NAP-AMR 2.0, released at WAAW 2025 [2]; predecessor NAP-AMR 2017–2021 [3]
Approach One Health: human, animal, agriculture, food and environment sectors [verify]
  • Key terms:
  • Antimicrobials: antibiotics, antivirals, antifungals and antiparasitics [verify].
  • AMR: microbes that no longer respond to the drugs used against them.
  • Bulk drug / API: the active ingredient.
  • Formulation: the finished dosage form.

5. Multi-Dimensional Analysis

Legal / Regulatory

  • Classing antimicrobials as "new drugs" brings every such product under the NDCT approval route, which tightens scrutiny before manufacturing licences are granted [1].
  • Antimicrobials would likely move from state-level generic licensing to central approval. This is a federal shift in drug regulation [verify].
  • A separate bulk-drug sale licence closes a gap where API trade was handled within the formulation licensing provisions [1].

Public Health

  • The proposal targets AMR, which is a major global public-health concern [1].
  • It supports NAP-AMR 2.0 objectives on rational antimicrobial use [2].

Economic / Industrial

  • India's generic-antibiotic industry would face higher compliance costs and possibly slower launches of new combinations [verify].
  • Bulk-drug licensing brings traceability to API trade. This matters for supply-chain integrity alongside the PLI scheme for APIs [verify].

Governance / Administrative

  • The central regulator's workload would grow, so CDSCO capacity and Centre–State coordination become critical [verify].
  • The proposal targets licences granted without adequate scrutiny, which points to weak oversight [1].

Environmental (One Health)

  • AMR spreads through pharma effluents, hospital waste and farm use. A national plan covering many sectors addresses this [2].

6. Recent Developments (last 12–18 months)

  • WAAW 2025 (November 2025): India releases the second National Action Plan on AMR (NAP-AMR 2.0) [2].
  • 20 Nov 2026: The Health Ministry proposes adding antimicrobials to the 'New Drug' definition under the NDCT Rules, 2019 [1].
  • 20 Nov 2026: The Ministry proposes a separate bulk-drug sale application form and licence form under the Drugs Rules, 1945 [1].

7. Prelims Hooks

  • The proposal amends the New Drugs and Clinical Trials Rules, 2019 to include 'antimicrobials' in the 'New Drug' definition [1].
  • Proposing ministry: Union Ministry of Health & Family Welfare, not the Department of Pharmaceuticals [1].
  • The bulk-drug sale licensing change is made under the Drugs Rules, 1945 [1].
  • The bulk-drug licence will be distinct from the licensing for formulations [1].
  • India's first NAP-AMR covered 2017–2021 [3].
  • NAP-AMR 2.0 was released during World AMR Awareness Week 2025 [2].
  • WHO India describes NAP-AMR (2017–21) as a technical document summarising AMR containment status [3].
  • WAAW is observed annually from 18–24 November [verify].
  • Schedule H1 of the Drugs Rules covers certain antibiotics and needs a prescription register [verify].
  • CDSCO is headed by the DCGI [verify].

8. How States Could License Antibiotics the Centre Never Approved

  • Two regulators, one gap between them
  • The Centre decides whether a new drug is safe and works. State drug authorities give the licences to make and sell drugs [6].
  • In 2012, the Parliamentary Standing Committee on Health looked at how CDSCO works. It covered the approval of new drugs and the banning of drugs [6].
  • A study of antibiotic use in India in 2019 named this overlap of central and State powers as one reason why so many antibiotics are used [4].

  • Why putting antimicrobials in the 'New Drug' definition matters

  • Once every antimicrobial counts as a 'New Drug', the Centre must approve it before anyone can get a manufacturing licence [1].
  • This goes straight at what the Ministry is worried about: licences given without proper checks [1].

  • The scale of the problem

  • The same study found that over half of the antibiotic formulations (finished medicines) used in India in 2019 were unapproved [4].
  • It also blamed the large number of FDCs (fixed-dose combinations, two or more drugs mixed in one pill) being made and sold [4].

9. Why Earlier Bans Did Not Clear the Shelves

  • A rule on paper is not a drug off the market
  • The government banned some unapproved FDCs, including antibiotic ones, most recently in 2016 [5].
  • Industry challenged the bans in court, and the FDCs seem to have stayed on sale [5].
  • So the new rule will be tested in the same way. Will the Centre enforce it against products that are already sold, or only against new applications?

  • Licensing controls the factory, not the chemist's counter

  • The 2019 study found most antibiotics could be bought over the counter (without a prescription) with no restriction. It called this a main reason for high use [4].
  • 'Watch' antibiotics made up 54.9% of all use, measured in DDDs (defined daily doses, a standard unit for counting how much of a drug is used) [4].
  • 'Watch' is a WHO group of antibiotics that carry a higher risk of resistance and should be used with care.
  • Stricter licences cannot change what a chemist sells. That needs enforcement at the retail level, and the proposal [1] does not cover it.

10. The Case Against Centralising, and What It Gets Right

  • The strongest objection: the Centre is stretched too
  • Moving every antimicrobial to central approval means CDSCO gets many more files. Approvals could slow down, and so could launches of cheap generics.
  • Parliament's own committees have said the drug-control system is weak at both levels. The 2013 Standing Committee report pointed to weak drug-control set-ups in the States and at the Centre [7].
  • This point is fair. A file moved to a busy office is not a file checked properly.

  • Why the shift still makes sense

  • The same 2013 committee recommended that the licensing of drug manufacture be centralised, because of these weaknesses [7].
  • Checking at one central point is easier to make consistent than 36 different State standards. This matters most for antimicrobials, where one bad approval adds to resistance everywhere [1].

  • What should go with it

  • MoHFW should add staff and deadlines to the rule. Centralising without more CDSCO capacity just moves the delay. The 2013 committee's push to centralise came with a call to fix weak drug-control infrastructure [7].

11. What the Bulk-Drug Licence Leaves Out: Factory Waste

  • Antibiotic pollution from factories is mostly unregulated
  • WHO says antibiotic pollution from manufacturing is largely unregulated. Normal quality checks usually ignore what a factory releases into the environment [8].
  • Antibiotic traces in factory wastewater can breed resistant microbes in rivers and soil. This is the One Health link (human, animal and environmental health are connected).

  • The new licence tracks who sells APIs, not what the plant releases

  • The draft creates a separate form and licence for selling bulk drugs [1]. It says nothing about discharge from API plants.
  • WHO's 2024 guidance covers every stage, from making APIs (active pharmaceutical ingredients) to the finished medicine and its packaging [8].

  • What could follow

  • CDSCO and pollution regulators could use WHO's discharge targets as a licence condition for bulk antibiotic makers. WHO wrote the 2024 guidance for regulators, buyers and inspectors, and allows a step-by-step rollout so that supply is not hurt [8].
  • Public buyers of antibiotics, who are also among WHO's intended users, could favour suppliers that meet these targets [8].

12. Anchors for Answers

  • Data: 'Watch'-group antibiotics made up 54.9% of India's antibiotic use (in DDDs) in 2019. Over half of the antibiotic formulations used that year were unapproved [4]
  • Report/Committee: 59th Report of the Parliamentary Standing Committee on Health on the functioning of CDSCO, 2012 [6]. The 2013 Standing Committee report recommended centralised licensing of drug manufacture [7]
  • Law/Case: NDCT Rules, 2019 ('New Drug' definition) and Drugs Rules, 1945 (bulk-drug sale licence), both under the Drugs and Cosmetics Act, 1940 [1]. The 2016 FDC ban was challenged in court by industry [5]
  • Comparison: WHO's 2024 Guidance on wastewater and solid waste management for manufacturing of antibiotics sets discharge targets from API making to finished product, which India's licensing does not yet cover [8]
  • Scheme: NAP-AMR 2.0 (released at WAAW 2025) is the policy framework this regulatory tightening serves [2]

13. Mains Relevance

14. Related Topics to Study Next

  • NAP-AMR 2.0 (2025–29): the policy framework this regulation serves [2].
  • Drugs and Cosmetics Act, 1940 and the proposed new Drugs, Medical Devices & Cosmetics Bill: the statutory base and its planned overhaul.
  • CDSCO, DTAB and DCC: the bodies that recommend and implement these changes.
  • Schedule H1 and the Red Line campaign: earlier curbs on antibiotic misuse.
  • Fixed-dose combination (FDC) bans: closely related regulation of antibiotic combinations.
  • PLI scheme for bulk drugs/APIs: links to the bulk-drug licensing reform.
  • WHO Global Action Plan on AMR and the 2024 UNGA High-Level Meeting on AMR: the international framework.
  • Kerala's KARSAP: the first state-level AMR action plan.

15. NCERT Concepts to Revise

  • Antimicrobial resistance (Geography): AMR is the public-health threat driving the proposal to tighten licensing of antimicrobial products.
  • New Drugs and Clinical Trials Rules, 2019 (Economy): These are the rules being amended so antimicrobials count as 'New Drug' needing central approval.
  • Drugs Rules, 1945 (Polity): The second amendment creates a separate bulk-drug sale licence and form under these rules.
  • Drugs and Cosmetics Act, 1940 (Polity): Parent law under which both sets of drug rules are made; base for understanding licensing.
  • Central Drugs Standard Control Organisation (Polity): National drug regulator that would handle new-drug approvals for antimicrobials, with States licensing otherwise.
  • National Action Plan on AMR (Economy): India's policy framework against AMR, which this regulatory tightening supports.
  • One Health (Geography): Approach linking human, animal and environmental health that underpins NAP-AMR 2.0 and AMR control.
  • Active pharmaceutical ingredient (Geography): Bulk drug means the active ingredient, the subject of the new separate sale licence.
  • Fixed-Dose Combination (Polity): Related regulation: irrational antibiotic combinations are treated as new drugs and banned centrally.
  • Cooperative federalism (Polity): Shifting antimicrobial approval from states to the Centre raises Centre–State regulatory coordination questions.
  • Production-linked incentive (Economy): PLI scheme for bulk drugs links to API sector policy and supply-chain reform.
  • Department of Pharmaceuticals (Polity): Trap: the Health Ministry proposes this, not the Department of Pharmaceuticals, which handles industry promotion.

16. Common Errors / Trap Areas

  • Wrong rules: The 'New Drug' definition change is under the NDCT Rules, 2019. The bulk-drug licence change is under the Drugs Rules, 1945. Don't swap them [1].
  • Wrong ministry: The Health Ministry is the proposer, not the Department of Pharmaceuticals (Ministry of Chemicals & Fertilizers) [1].
  • Draft vs notified: In Nov 2026 these were proposed amendments, not final law [1].
  • NAP-AMR versions: The first plan ran 2017–2021 [3]. Version 2.0 was released at WAAW 2025 [2].
  • Bulk drug ≠ formulation: The reform creates separate licensing for the API, not the finished dosage form [1].

Sources

  1. 1Ministry seeks tighter norms for antimicrobials, bulk trade — The Hindu, 20 Nov 2026 (Page 6)thehindu.com · tier 4
  2. 2WAAW 2025: India's much awaited second version of the National Action Plan on AMR released — Down To Earthdowntoearth.org.in · tier 4
  3. 3National action plan on antimicrobial resistance (NAP-AMR) 2017–2021 — WHO India — )-2017---2021who.int · tier 2
  4. 4Over half the antibiotic formulations India used in 2019 were unapproved — Down To Earthdowntoearth.org.in · tier 4
  5. 5Indian government is not doing enough to tackle the sale of unapproved antibiotics — Down To Earthdowntoearth.org.in · tier 4
  6. 6Lapses in the process of drug approval in India — PRS Legislative Research blogprsindia.org · tier 1
  7. 7Standing Committee Report on drugs bill, 2013 — PRS Legislative Researchprsindia.org · tier 1
  8. 8Guidance on wastewater and solid waste management for manufacturing of antibiotics — WHOwho.int · tier 2
At the end · practice MCQs
2 questions on this article
Check the answer for each question, or reveal all at once.
Practice MCQs →

Mains Q&A on this note

NCERT concepts in this note

Also on 20 November

All 20 November articles →